Swissmedic publishes Information concerning an official Warning from Brazil regarding Falsified Medicinal Product
![GDP in Switzerland (GDP 3)](files/eca/userImages/training.img/Z-GDP3-GDP-in-Switzerland-neues-Layout.jpg)
Recommendation
12 September 2024
Basel, Switzerland
Specifics in the Distribution of Medicinal Products (Course in english language!)
The Swissmedic has been informed by the Brazilian Health Regulatory Agency ANVISA that Brazil has suspended all imports of medicinal products from three Turkish wholesalers. The reason for this is the export of falsified units from Turkey to Brazil. One of the batches was also obtained from Turkey and sold to Brazil by a Swiss wholesaler.
In this regard, an information for Swiss companies was published. The Swissmedic points out that Swiss companies are also not permitted to supply medications obtained from the Turkish wholesalers to Brazil.
The names of the three wholesalers and further information can be found on the website of Swissmedic.
Related GMP News
16.07.2024Templates for Shortage Prevention and Mitigation Plans issued by EMA
16.07.2024New Measures to Report Medicine Disappearances
16.07.2024GDP Non-Compliance Report for Czech Wholesale Distributor
16.07.2024Checklist for Implementation of GDP Principles - Part 9: Transportation
12.06.2024EU adopts Supply Chain Law - Implications for pharmaceutical Companies